CN | Jotup

CN Releases 2022 Sustainability Data Supplement

Retrieved on:

Friday, June 30, 2023

Independent Board for Presbyterian Foreign Missions, Tree, Carbon accounting, Woman, CN, GHG, Federal Railroad Administration, FRA, Renewable energy, Recycling, Construction, Nursing

In 2022, CN reduced its GHG emission intensity for Scope 3 fuel-and-energy-related activities by 4.3% from 2021.

Key Points:

In 2022, CN reduced its GHG emission intensity for Scope 3 fuel-and-energy-related activities by 4.3% from 2021.
In 2022, CN diverted approximately 94% of its waste from landfill nearly achieving its annual target.
In 2022, CN planted 114,000 trees and realized a 77% progress towards its 2030 target.
In 2022, CN improved its injury frequency rate, based on the Federal Railroad Administration (FRA) methodology, by 19% from 2021.

Canadian Start-Up Making Waves in Quantum-Inspired Technology

Retrieved on:

Tuesday, June 27, 2023

InfinityQ is a dynamic start-up that delivers quantum-inspired optimisation of exponentially hard problems that classic computers cannot tackle.

Key Points:

InfinityQ is a dynamic start-up that delivers quantum-inspired optimisation of exponentially hard problems that classic computers cannot tackle.
Simply put: InfinityQ’s Quantum-Inspired Technology bridges the gap between the real and quantum world to solve problems with optimal solutions that save money and are fast, flexible, simple and green.
Our technology delivers real-time optimal solutions to the most difficult problems at tremendous speed, despite the number of variables.
Because our technology works at incredibly high speed, our solutions can optimize accuracy and performance challenges for multiple businesses.

Mabwell Announces the U.S. FDA approval of 9MW3811 for IND

Retrieved on:

Thursday, June 15, 2023

Macrophage, Clinical trial, CN, Trial of the century, Pulmonary fibrosis, Fibrosis, AUS, Mouse, Neoplasm, FDA, IND, Tumor microenvironment, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Vaccine

As China's First anti-IL-11 monoclonal antibody approved to clinical study, 9MW3811 has received IND clearance in three countries (AUS, CN & USA).

Key Points:

As China's First anti-IL-11 monoclonal antibody approved to clinical study, 9MW3811 has received IND clearance in three countries (AUS, CN & USA).
9MW3811 is a humanized monoclonal antibody against human interleukin-11 (IL-11) independently developed by Mabwell.
9MW3811 can effectively block the activation of the downstream signaling pathway of IL-11 and inhibit the pathophysiological functions induced by IL-11, thereby achieving the therapeutic effect on fibrosis and tumor.
9MW3811 is in dose escalation study in Australia and expected to have good safety profile according to existing data.

Cipher Neutron Signs Collaboration Agreement with Ionomr to Create North America's First 250-Kilowatt AEM Hydrogen Electrolyzer

Retrieved on:

Tuesday, June 13, 2023

Neutron, Hydrogen, PGM, AEM, Electrolysis, Solid oxide electrolyzer cell, PFAS, Anion exchange membrane, Hydrogen economy, Research, CN, Watt, Greenhouse gas emissions, Platinum, Lithium, Palladium, Green hydrogen, Collaboration

Toronto, Ontario--(Newsfile Corp. - June 13, 2023) - Cipher Neutron Inc. ("Cipher Neutron") and Ionomr Innovations Inc. ("Ionomr") are pleased to jointly announce that they have entered into a significant Collaboration Agreement (the "Collaboration").

Key Points:

Toronto, Ontario--(Newsfile Corp. - June 13, 2023) - Cipher Neutron Inc. ("Cipher Neutron") and Ionomr Innovations Inc. ("Ionomr") are pleased to jointly announce that they have entered into a significant Collaboration Agreement (the "Collaboration").
Smaller AEM Electrolyzers are not expected by Cipher Neutron and Ionomr to provide the cost advantages as those of the proposed 250-Kilowatt AEM Electrolyzers that Cipher Neutron and Ionomr are developing under the Collaboration.
Under the Collaboration, Ionomr and Cipher Neutron will bring innovative Electrolyzer and fuel cell membrane technology together with advanced AEM Technology to create the first North American-made 250-Kilowatt AEM Hydrogen Electrolyzer, and the only 100% made in Canada solution on the market.
Cipher Neutron recently unveiled the world's first commercial 10-Kilowatt AEM Hydrogen Electrolyzer at the Canadian Hydrogen Convention.

SCOTTIE RESOURCES REPORTS POSITIVE INITIAL METALLURGICAL TEST RESULTS FOR BLUEBERRY ZONE WITH UP TO 97.6% GOLD RECOVERY

Retrieved on:

Tuesday, June 13, 2023

Silver, GRG, Gold, Risk, CN, Mining, Uranium mining

These promising initial metallurgical results illustrate strong gold recoveries using multiple extraction techniques and by doing so substantially de-risk the project.

Key Points:

These promising initial metallurgical results illustrate strong gold recoveries using multiple extraction techniques and by doing so substantially de-risk the project.
With so many advantages to the deposit: high-grade, near surface, on a road, adjacent to high-voltage power – these results confirming the deposit's metallurgy adds yet another positive element."
Direct CN leach test results show that 97.6% of the gold can be extracted with a grind size of p80 of 25 μm.
The total silver recovery of 88.6% with a grade of 31.9 g/t Ag was achieved in the same test.

CN Bio Appoints Dr. Samantha Macro as Chief Financial Officer

Retrieved on:

Tuesday, June 6, 2023

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that it has appointed Dr. Samantha Macro as Chief Financial Officer.

Key Points:

CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced that it has appointed Dr. Samantha Macro as Chief Financial Officer.
Samantha joins CEO, Dr. Paul Brooks, on the executive team to guide all key commercial and strategic initiatives, drive revenue and shape CN Bio’s ongoing growth trajectory.
Ahead of transitioning into life sciences, Samantha qualified as a chartered accountant at PwC and held senior roles at PwC and Aviva.
Dr. Samantha Macro, CFO, CN Bio, commented: “CN Bio’s OOC solutions are disruptive within the sector; capable of accurately and efficiently predicting human responses to medicines.

CN Among Global Leaders in Sustainability

Retrieved on:

Friday, June 2, 2023

CNR, United Nations, Dow Jones, Climate change, CN, Trust, United, UN, CDP, TSX, CNI, NYSE, Safety, Management

MONTREAL, June 02, 2023 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) is proud to be part of the United Nations Vision 2045 documentary film series.

Key Points:

MONTREAL, June 02, 2023 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) is proud to be part of the United Nations Vision 2045 documentary film series.
CN is building on its decarbonization initiatives, its deployment of operating technologies to drive safety and efficiency, its focus on making CN a great place to work, and by engaging with all stakeholders with trust and transparency.
CN's sustainability leadership is recognized through its inclusion in the Dow Jones Sustainability World and North American Indices.
CN has also been recognized for its climate leadership, securing a place on CDP's prestigious Climate Change "A" List.

TCRC Ratifies CN Collective Agreement

Retrieved on:

Friday, May 26, 2023

CNR, Conductor, TSX, TCRC, CNI, Conference, NYSE, CN, Management

MONTREAL, May 26, 2023 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that the Teamsters Canada Rail Conference (TCRC) has ratified its collective agreement with the Company.

Key Points:

MONTREAL, May 26, 2023 (GLOBE NEWSWIRE) -- CN (TSX: CNR) (NYSE: CNI) announced today that the Teamsters Canada Rail Conference (TCRC) has ratified its collective agreement with the Company.
The union represents approximately 6,000 CN Locomotive Engineers, Conductors, Yard Conductors, and Yard Coordinators working in Canada.
“We are pleased that TCRC members have ratified the collective agreement reached earlier this year.
We thank the TCRC leadership for their engagement throughout this process.

Suzuki, Daihatsu, and Toyota to Unveil Mini-Commercial Van Electric Vehicles

Retrieved on:

Wednesday, May 17, 2023

BEV, Transport, Bev, Exhibition, Japan Automobile Manufacturers Association, Carbon, CN, JAMA, Automotive industry, Daihatsu, Suzuki

Toyota City, Japan, May 17, 2023 - (JCN Newswire) - Suzuki Motor Corporation (Suzuki), Daihatsu Motor Co., Ltd. (Daihatsu), and Toyota Motor Corporation (Toyota) will unveil prototype mini-commercial van electric vehicles (BEVs) equipped with a jointly developed BEV system.

Key Points:

Toyota City, Japan, May 17, 2023 - (JCN Newswire) - Suzuki Motor Corporation (Suzuki), Daihatsu Motor Co., Ltd. (Daihatsu), and Toyota Motor Corporation (Toyota) will unveil prototype mini-commercial van electric vehicles (BEVs) equipped with a jointly developed BEV system.
The exhibition event will be organized by the Japan Automobile Manufacturers Association (JAMA) along with the G7 Hiroshima Summit.
Daihatsu will produce the vehicles, and Suzuki, Daihatsu, and Toyota will each release their own version within fiscal 2023.
The three companies Suzuki, Daihatsu, and Toyota will continue to promote efforts to achieve CN by providing sustainable means of transportation.

X4 Pharmaceuticals Announces Positive Phase 3 Results Showing Mavorixafor Reduced the Rate, Severity, and Duration of Infections vs. Placebo in Participants Diagnosed with WHIM Syndrome

Retrieved on:

Tuesday, May 16, 2023

Infection, WHIM syndrome, Arm, Therapy, European Hematology Association, WHIM, Federation of Clinical Immunology Societies, CIS, CN, Patient, Immune system, EHA, Rare, FDA, Caregiver, Pharmaceutical industry

Following the announcement of positive top-line data from the 4WHIM trial in November 2022, today’s event focuses on the impact of mavorixafor on the rate, severity, and duration of infections in trial participants.

Key Points:

Following the announcement of positive top-line data from the 4WHIM trial in November 2022, today’s event focuses on the impact of mavorixafor on the rate, severity, and duration of infections in trial participants.
“Today, we’re announcing that mavorixafor treatment demonstrated statistically significant and clinically meaningful improvements across a number of key infection metrics versus placebo in our pivotal, Phase 3 trial in those diagnosed with WHIM Syndrome,” said Paula Ragan, Ph.D., President and Chief Executive Officer of X4 Pharmaceuticals.
Approximately 90% of participants in the trial continued on to receive mavorixafor treatment in the ongoing open-label extension study.
The X4 live-event webcast presentation and the accompanying slides are now accessible on the investor relations section of the X4 website at www.x4pharma.com .